Stroke stem cell therapy (RESSTORE) - Histocell

Drug Profile

Stroke stem cell therapy (RESSTORE) - Histocell

Latest Information Update: 15 Jul 2016

Price : $50

At a glance

  • Originator Histocell
  • Developer Histocell; University Hospital Grenoble
  • Class Antihyperglycaemics; Cell therapies
  • Mechanism of Action Cell replacements; Stem cell stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Stroke

Most Recent Events

  • 01 Sep 2015 Phase-II clinical trials in Stroke in Czech Republic (IV)
  • 01 Sep 2015 Phase-II clinical trials in Stroke in Finland (IV)
  • 01 Sep 2015 Phase-II clinical trials in Stroke in France (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top